Capital Analysts LLC Buys Shares of 4,616 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Capital Analysts LLC bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,616 shares of the company’s stock, valued at approximately $102,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TEVA. FMR LLC boosted its position in shares of Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after buying an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after buying an additional 4,418,961 shares during the last quarter. Todd Asset Management LLC acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth $58,243,000. Marshall Wace LLP increased its holdings in Teva Pharmaceutical Industries by 87.8% during the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company’s stock worth $113,625,000 after buying an additional 2,410,420 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Teva Pharmaceutical Industries during the fourth quarter worth $38,914,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 1.1 %

TEVA opened at $15.03 on Tuesday. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a 50-day simple moving average of $15.19 and a 200 day simple moving average of $17.55. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $17.04 billion, a price-to-earnings ratio of -10.37, a P/E/G ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on TEVA shares. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Bank of America reduced their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.